D4476, a cell-permeant inhibitor of CK1δ (IC90 <10 uM), suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a, D4476 originally identified as inhibitors of activin receptor-like kinase ALK5.

D159687 is a selective negative allosteric modulator (NAM) of PDE4D.

CZC-54252 is a potent inhibitor of leucine-rich repeat kinase 2 (LRRK2) (IC50 values are 1.28 nM and 1.85 nM for wild-type and G2019S mutant forms of LRRK2 respectively).

CZC-25146 is a potent, selective and metabolically stable LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.

CZC24832 is the first selective PI3Kγinhibitor with IC50 of 27 nM, with 10-fold selectivity over PI3Kβ and >100-fold selectivity over PI3Kα and PI3Kδ.

CZ415 is a potent and highly selective mTOR inhibitor.

CYT387 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 11 nM and 18 nM, respectively.

CYM5541 is a selective sphingosine-1-phosphate receptor 3 (S1P3) allosteric agonist (EC50 = 72-132 nM).

CYM-5442 is a highly-selective S1P1 (Spingosine 1-Phosphate Receptor 1) agonist.

Cyclovirobuxin D(Bebuxine)

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities.

Cyclopamine(11-Deoxojervine) is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM.

Cyclobenzaprine Hcl is a skeletal muscle relaxant and a central nervous system (CNS) depressant.

Cyclo (RGDfC), avb3 Integrin Binding Cyclic RGD Peptide,This is a cyclic RGDfC sequence, an integrin avb3-affine peptide.

CY-09 is an NLRP3 inhibitor.

CX-6258 is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity.

CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA, has no effect on Pol II, and possesses 250-to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation.

CX-4945 (Silmitasertib) is a potent and selective ATP-competitive small molecule protein kinase CK2 inhibitor with a Ki and an IC50 of 0.38 and 1 nM for recombinant human CK2α, respectively.

CW-069 is a novel and allosteric inhibitor of the microtubule motor protein HSET with IC50 value of 75 ± 20 μM; shows statistically significant selectivity over KSP.

CVT-313(NG-26) is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).

CUDC-907 (PI3K/HDAC Inhibitor I) is a dual PI3K and HDAC inhibitor for PI3Kɑ, HDAC1, HDAC2, HDAC3 and HDAC10 with IC50 of 19 nM, 1.7 nM, 5 nM, 1.8 nM and 2.8 nM, respectively.

CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.

CU-CPT9b is an antagonist of toll-like receptor 8 (TLR8; Kd = 21 nM).

CTX-0294885 is a novel broad-spectrum kinase inhibitor.

CTPI-2 (SLC25A1 inhibitor CTPI-2) is a novel specific SLC25A1 inhibitor with Kd of 3.5 uM, CTPI-2 is synthetic lethal with cisplatin or with EGFR inhibitor co-treatment and restores antitumor responses both in vitro and in vivo; disrupts self-renewal and

Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB

CPI-637 is a potent and selective CBP/EP300 bromodomains inhibitor with IC50 of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respectively.

CPI-444 is an orally administered antagonist of the adenosine A2A receptor. It is designed to block the action of adenosine that is produced by tumors.

CPI203 is a novel potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 with an IC50 of ~37 nM (BRD4 α-screen assay).

CPI-169 racemate is the racemate form of CPI-169, which is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2); decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apo